Design Therapeutics Inc (DSGN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $12.24 (-4.45%), Market cap $0.83B, 52-week low–high $3.21 ~ $15.79.
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inhe
Financial statements, price targets, institutional (13F) holdings and related news for Design Therapeutics Inc are updated in real time on BlackAll Trade.
Design Therapeutics Inc trades at $12.24 (-4.45%). Real-time quotes and charts are available on BlackAll Trade.
Design Therapeutics Inc has a market cap of about $0.83B.
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the Unit